Additional correction of OAB symptoms by two anti-muscarinics for men over 50 years old with residual symptoms of moderate prostatic obstruction after treatment with Tamsulosin

Figures & data

Figure 1. Algorithm for the examination and treatment (n = 417). USP, ultrasound of the prostate; UD, urodynamics; I-RSS, international system of total symptom scores in prostate diseases; OAB-AT, OAB Awareness Tool – questionnaire to assess the symptoms of overactive bladder.

Table 1. Change in I-PSS and prostate volume at the start and after treatment (in scores).

Observation period parameters	Before treatment (n = 417)	After Treatment Tamsulosin 0.4 mg per day (n = 313)	After placebo (n = 114)	After treatment Solifenacin 5 mg + Trospium 5 mg (n = 139)	After placebo (n = 98)
Incomplete emptying	2.2 (0.6)	1.3 (0.7)	1.9 (1.1)	1.1 (0.5)*	1.7 (0.5)
Intermittency	1.9 (0.9)	1.5 (0.7)	1.7 (1.0)	1.3 (0.8)	1.7 (1.2)
Weak stream	2.5 (0.6)	1.1 (0.5)*	2.7 (1.4)	1.3 (0.6)*	2.3 (0.8)
Straining	1.6 (0.5)	0.7 (0.5)*	1.2 (1.1)	0.7 (0.6)	1.0 (0.5)
Nocturia	2.7 (0.7)	1.7 (0.6)	2.6(1.1)	1.2 (0.5)*	2.3 (1.4)
Prostate volume, ml	27.8 (7.3)	24.1 (6.9)	27.5 (7.4)	25.2 (8.3)	27.4 (6.9)

SD, standard deviation. *p < 0.05.

Table 2. Change in OAB-AT and urodynamic symptoms at the start and after treatment.

Observation period parameters	Before treatment (n = 417)	After treatment Tamsulosin 0.4 mg per day (n = 313)	Placebo (n = 114)	After treatment Solifenacin 5 mg + Trospium 5 mg (n = 139)	Placebo (n = 98)
Daytime frequency (in points)	2.2 (1.1)	1.6 (0.8)	1.9 (1.6)	1.3 (0.5)	1.7 (1.6)
Night-time frequency (in points)	1.9 (0.9)	1.2 (1.2)	2.1 (1.3)	0.6 (0.5)*	1.9 (0.7)
Urgency (in points)	2.4 (0.8)	1.9 (1.0)	2.2 (1.3)	0.9 (0.5)*	1.7 (0.6)
Urgency incontinence (in points)	2.5 (0.7)	1.5 (0.8)	2.7 (1.4)	0.7 (0.7)*	1.6 (1.)
PVR, ml	17.5 (5.8)	19.8 (4.9)	19.0 (6.2)	27.9 (5.3)	18.1 (4.8)
Qaver, ml/s	12.8 (6.1)	19.8 (5.7)	15.8 (4.9)	21.5 (4.1)*	13.7 (5.2)
Qmax, ml/s	16.9 (3.3)	25.6 (4.2)*	17.4 (9.3)	26.6 (5.1)*	15.5 (7.3)

PVR, postvoid residual urine volume; Q_aver, average flow rate, Q_max, maximum flow rate; SD, standard deviation. *p < 0.05.

Figure 2. Changing some parameters of state off LUTs patients during treatment with tamsulosin and combination anti-muscarinic drugs. ES, episodes of straining; EWS, episodes of weak stream; EU, episodes of urgency, episodes of urgency incontinence (per day).